AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in the confirmatory Phase III PROLONG trial to reduce the risk of

Read the full 463 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE